Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an update.
Radiopharm Theranostics Limited has announced the application for quotation of new securities on the Australian Securities Exchange (ASX). The company plans to quote 750,960,477 ordinary fully paid shares and 1,166,666,667 options expiring in 2027, which could potentially strengthen its financial position and support its strategic growth initiatives in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company aims to enhance the precision and effectiveness of cancer treatment through its innovative theranostic solutions.
Average Trading Volume: 5,896,644
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.